SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Friberg K)
 

Search: WFRF:(Friberg K) > (2010-2019) > Antithrombotic ther...

  • Batra, GoravUppsala universitet,Uppsala University,Kardiologi,Uppsala kliniska forskningscentrum (UCR) (author)

Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2017-11-06
  • Oxford University Press (OUP),2018
  • 10 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:c76589e1-2b48-4bcf-8224-d773777ad56b
  • https://lup.lub.lu.se/record/c76589e1-2b48-4bcf-8224-d773777ad56bURI
  • https://doi.org/10.1093/ehjcvp/pvx033DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-320310URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:139748155URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Aims Optimal antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI) and atrial fibrillation is uncertain. In this study, we compared antithrombotic regimes with regard to a composite cardiovascular outcome of all-cause mortality, MI or ischaemic stroke, and major bleeds. Methods and results Patients between October 2005 and December 2012 were identified in Swedish registries, n = 7116. Landmark 0-90 and 91-365 days of outcome were evaluated with Cox-regressions, with dual antiplatelet therapy as reference. At discharge, 16.2% received triple therapy (aspirin, clopidogrel, and warfarin), 1.9% aspirin plus warfarin, 7.3% clopidogrel plus warfarin, and 60.8% dual antiplatelets. For cardiovascular outcome, adjusted hazard ratio with 95% confidence interval (HR) for triple therapy was 0.86 (0.70-1.07) for 0-90 days and 0.78 (0.58-1.05) for 91-365 days. A HR of 2.16 (1.48-3.13) and 1.61 (0.98-2.66) during 0-90 and 91-365 days, respectively, was observed for major bleeds. For aspirin plus warfarin, HR 0.82 (0.54-1.26) and 0.62 (0.48-0.79) was observed for cardiovascular outcome and 1.30 (0.60-2.85) and 1.01 (0.63-1.62) for major bleeds during 0-90 and 91-365 days, respectively. For clopidogrel plus warfarin, HR of 0.90 (0.68-1.19) and 0.68 (0.49-0.95) was observed for cardiovascular outcome and 1.28 (0.71-2.32) and 1.08 (0.57-2.04) for major bleeds during 0-90 and 91-365 days, respectively. Conclusion Compared to dual antiplatelets, aspirin or clopidogrel plus warfarin therapy was associated with similar 0-90 days and lower 91-365 days of risk of the cardiovascular outcome, without higher risk of major bleeds. Triple therapy was associated with non-significant lower risk of cardiovascular outcome and higher risk of major bleeds.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Friberg, LeifKarolinska Institutet,Karolinska Institute (author)
  • Erlinge, DavidLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)kard-der (author)
  • James, Stefan K,1964-Uppsala universitet,Uppsala University,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)stjam367 (author)
  • Jernberg, TomasKarolinska Institutet,Karolinska Institute,Karolinska University Hospital (author)
  • Svennblad, BodilUppsala universitet,Uppsala University,Uppsala University Hospital,Uppsala kliniska forskningscentrum (UCR),Ortopedi(Swepub:uu)bosve677 (author)
  • Wallentin, Lars,1943-Uppsala universitet,Uppsala University,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall (author)
  • Oldgren, Jonas,1964-Uppsala universitet,Uppsala University,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)jonaoldg (author)
  • Uppsala UniversityKardiologi (creator_code:org_t)

Related titles

  • In:European Heart Journal - Cardiovascular Pharmacotherapy: Oxford University Press (OUP)4:1, s. 36-452055-68372055-6845

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view